Asset Details
Do you wish to reserve the book?
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
Do you wish to request the book?
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
2016
Overview
Acute myeloid leukemia (AML) cells require BRD9 to regulate
MYC
gene expression and prevent myeloid differentiation. Selective inhibition of BRD9 using a chemical probe that was validated using a resistant bromodomain-swap allele of
BRD9
limits AML cell growth.
Here we show that acute myeloid leukemia (AML) cells require the BRD9 subunit of the SWI−SNF chromatin-remodeling complex to sustain
MYC
transcription, rapid cell proliferation and a block in differentiation. Based on these observations, we derived small-molecule inhibitors of the BRD9 bromodomain that selectively suppress the proliferation of mouse and human AML cell lines. To establish these effects as on-target, we engineered a bromodomain-swap allele of
BRD9
that retains functionality despite a radically altered bromodomain pocket. Expression of this allele in AML cells confers resistance to the antiproliferative effects of our compound series, thus establishing BRD9 as the relevant cellular target. Furthermore, we used an analogous domain-swap strategy to generate an inhibitor-resistant allele of
EZH2
. To our knowledge, our study provides the first evidence for a role of BRD9 in cancer and reveals a simple genetic strategy for constructing resistance alleles to demonstrate on-target activity of chemical probes in cells.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ 13
/ 13/106
/ 13/109
/ 13/44
/ 38
/ 38/39
/ Alleles
/ Animals
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Cell Differentiation - drug effects
/ Cell Proliferation - drug effects
/ Dose-Response Relationship, Drug
/ Drug Resistance, Neoplasm - drug effects
/ Drug Screening Assays, Antitumor
/ Humans
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - metabolism
/ Leukemia, Myeloid, Acute - pathology
/ Mice
/ Probes
/ Structure-Activity Relationship
/ Transcription Factors - antagonists & inhibitors
